Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

Xie J, Xiao D, Zhao J, Hu N, Bao Q, Jiang L, Yu L

Advanced healthcare materials29 Mar 2016Cited by 18 (Europe PMC)

PMID27028159DOI10.1002/adhm.201500996PepBankPUB-27028159

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cibinetide (ARA-290).

01AnimalNot a test of Cibinetide (ARA-290) aloneAnimal study (in vivo)Efficacy outcome
In mice with chronic constriction injury, the THC-MSN-ARA290 nanocomplexes attenuated inflammation.
In plain wordsIn mice with nerve injury, nanoparticles carrying THC and ARA290 together reduced inflammation. This does not show that ARA290 alone does this.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseInflammation in vivo (THC-MSN-ARA290)
Study
mousen: not reported in source
chronic constriction injury neuropathic pain model
Outcome group
Inflammation markers · Nervous system and cognition
Source sentences
Summary
It is found that the nanocomplexes attenuate in vitro and in vivo inflammation, and achieve a sustained relief of neuropathic pain in injured animals induced by both thermal hyperalgesia and mechanical allodynia.
1 context sentence(design, population, supporting numbers)
Summary · context
The biosafety and anti-inflammatory effects of the nanocomplexes are first evaluated in primary microglia in vitro, and further in a mouse model of chronic constriction injury.
In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).
Report a problemFND-2702815902
02AnimalNot a test of Cibinetide (ARA-290) aloneAnimal study (in vivo)Efficacy outcome
In mice with chronic constriction injury, the THC-MSN-ARA290 nanocomplexes achieved sustained relief of neuropathic pain from thermal hyperalgesia.
In plain wordsIn mice with nerve injury, nanoparticles with THC and ARA290 together gave lasting relief from heat pain sensitivity. The result is for the combination.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseThermal hyperalgesia (THC-MSN-ARA290)
Study
mousen: not reported in source
chronic constriction injury neuropathic pain model
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
It is found that the nanocomplexes attenuate in vitro and in vivo inflammation, and achieve a sustained relief of neuropathic pain in injured animals induced by both thermal hyperalgesia and mechanical allodynia.
1 context sentence(design, population, supporting numbers)
Summary · context
The biosafety and anti-inflammatory effects of the nanocomplexes are first evaluated in primary microglia in vitro, and further in a mouse model of chronic constriction injury.
In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).
Report a problemFND-2702815903
03AnimalNot a test of Cibinetide (ARA-290) aloneAnimal study (in vivo)Efficacy outcome
In mice with chronic constriction injury, the THC-MSN-ARA290 nanocomplexes achieved sustained relief of neuropathic pain from mechanical allodynia.
In plain wordsIn mice with nerve injury, nanoparticles with THC and ARA290 together gave lasting relief from touch pain sensitivity. The result is for the combination.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseMechanical allodynia (THC-MSN-ARA290)
Study
mousen: not reported in source
chronic constriction injury neuropathic pain model
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
It is found that the nanocomplexes attenuate in vitro and in vivo inflammation, and achieve a sustained relief of neuropathic pain in injured animals induced by both thermal hyperalgesia and mechanical allodynia.
1 context sentence(design, population, supporting numbers)
Summary · context
The biosafety and anti-inflammatory effects of the nanocomplexes are first evaluated in primary microglia in vitro, and further in a mouse model of chronic constriction injury.
In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).
Report a problemFND-2702815904
04LabNot a test of Cibinetide (ARA-290) aloneIn vitro (cells)Efficacy outcome
In primary microglia, the THC-MSN-ARA290 nanocomplexes attenuated inflammation.
In plain wordsIn cells, nanoparticles carrying THC and ARA290 together reduced inflammation. This does not show that ARA290 alone does this.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseInflammation in primary microglia (THC-MSN-ARA290)
Study
n: not reported in source
primary microglia
Outcome group
Inflammation markers · Nervous system and cognition
Source sentences
Summary
It is found that the nanocomplexes attenuate in vitro and in vivo inflammation, and achieve a sustained relief of neuropathic pain in injured animals induced by both thermal hyperalgesia and mechanical allodynia.
1 context sentence(design, population, supporting numbers)
Summary · context
The biosafety and anti-inflammatory effects of the nanocomplexes are first evaluated in primary microglia in vitro, and further in a mouse model of chronic constriction injury.
In this study, Cibinetide (ARA-290) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cibinetide (ARA-290).
Report a problemFND-2702815901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.